Get the Stockscreener App
78.47
2.63%
2.01
Ptc Therapeutics Inc stock is traded at $78.47, with a volume of 1.33M.
It is up +2.63% in the last 24 hours and up +16.82% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
See More
Previous Close:
$76.46
Open:
$76.54
24h Volume:
1.33M
Relative Volume:
1.11
Market Cap:
$6.30B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-13.21
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
+4.21%
1M Performance:
+16.82%
6M Performance:
+69.81%
1Y Performance:
+82.96%
1-Day Range:
$75.34
$79.98
1-Week Range:
$74.02
$79.98
52-Week Range:
$35.95
$79.98
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
78.47 | 6.14B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
Geode Capital Management LLC Boosts Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Catalyst Funds Management Pty Ltd Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Neo Ivy Capital Management Lowers Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
4,537 Shares in PTC Therapeutics, Inc. $PTCT Bought by CFC Planning Co LLC - MarketBeat
Ptc Therapeutics stock hits all-time high at 78.75 USD By Investing.com - Investing.com Nigeria
Ptc Therapeutics stock hits all-time high at 78.75 USD - Investing.com
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,812 Shares - MarketBeat
Leerink Partnrs Has Negative Outlook of PTCT FY2026 Earnings - MarketBeat
PTC Therapeutics (NASDAQ: PTCT) sets Dec. 2 R&D Day in New York, pipeline updates - Stock Titan
Why PTC Therapeutics Inc. (BH3) stock is a must watch tickerJuly 2025 Momentum & Safe Capital Growth Trade Ideas - newser.com
Published on: 2025-11-20 03:07:50 - newser.com
What downside risks could hit PTC Therapeutics Inc. (BH3) stockJuly 2025 Reactions & Capital Efficient Trading Techniques - newser.com
PTC Therapeutics Inc. (PTCT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will PTC Therapeutics Inc. (BH3) stock benefit from mergersProduct Launch & Real-Time Volume Analysis Alerts - newser.com
Duchenne Muscular Dystrophy Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Sarepta Therapeutics, PTC Therapeutics, Nippon Shinyaku, Santhera Pharmaceuticals - Barchart.com
PTC Therapeutics Executive Sells Shares - TradingView
VP Boulding Sells 2,812 ($213.7K) Of PTC Therapeutics Inc [PTCT] - TradingView
[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
Can PTC Therapeutics Inc. stock reach $100 price targetJuly 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
PTC Therapeutics stock rating reiterated by Cantor Fitzgerald at Overweight - Investing.com Canada
Will PTC Therapeutics Inc. (BH3) stock deliver stable dividends2025 Market Sentiment & Breakout Confirmation Alerts - newser.com
Rockefeller Capital Management L.P. Buys 7,751 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
Bank of New York Mellon Corp Acquires 49,728 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
(PTCT) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
PTC Therapeutics (NASDAQ:PTCT) Nasdaq Composite Shows Trial Motion - Kalkine Media
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why - AOL.com
PTC Therapeutics (NASDAQ:PTCT) Reaches New 52-Week HighHere's Why - MarketBeat
Is PTC Therapeutics Inc. stock a top pick in earnings season2025 Price Momentum & High Return Stock Watch Alerts - newser.com
Savant Capital LLC Sells 5,487 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics at Jefferies: Strategic Moves in Rare Disease By Investing.com - Investing.com Canada
Can PTC Therapeutics Inc. stock sustain revenue growthEarnings Growth Report & Free Expert Verified Stock Movement Alerts - newser.com
VP Boulding Files To Sell 2,812 Of PTC Therapeutics Inc [PTCT] - TradingView
9,941 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Vise Technologies Inc. - MarketBeat
Emma Reeve Sells 7,333 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (PTCT) Price Target Increased by 15.54% to 80.45 - Nasdaq
PTC Therapeutics, Inc. $PTCT Shares Sold by Candriam S.C.A. - MarketBeat
Sector ETF performance correlation with PTC Therapeutics Inc.IPO Watch & Community Driven Trade Alerts - newser.com
Campbell & CO Investment Adviser LLC Acquires Shares of 14,893 PTC Therapeutics, Inc. $PTCT - MarketBeat
Aviva PLC Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Published on: 2025-11-16 01:11:13 - newser.com
How PTC Therapeutics Inc. stock compares to growth peersWeekly Investment Report & Weekly Stock Performance Updates - newser.com
Jupiter Asset Management Ltd. Invests $2.25 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
Is PTC Therapeutics Inc. (BH3) stock safe for risk averse investors2025 Momentum Check & Low Risk High Win Rate Picks - newser.com
Ptc Therapeutics stock hits 52-week high at 76.11 USD By Investing.com - Investing.com Canada
PTC Therapeutics Director Emma Reeve Sells 7,333 Shares - TradingView
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):